BioCentury
ARTICLE | Product Development

Intellia delivers transformative potential with in vivo gene editing 

Intellia’s CRISPR-Cas9 platform threatens to disrupt other new modality markets

June 26, 2021 3:17 PM UTC

Intellia and partner Regeneron have generated the first clinical data indicating CRISPR-based gene editing may live up to its promise of creating one-time, curative therapies for systemic diseases — a breakthrough that represents a looming threat to other new modalities.

The data, though only from six patients, provide the first hint that CRISPR-based therapies could displace other new modalities in indications where those technologies are just finding a footing on the market. Still, critical questions of durability, off-target editing and delivery beyond the liver need to be answered to assess the reach of the technology’s disruptive potential, and how quickly it can get there...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article